Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
O76080
UPID:
ZFAN5_HUMAN
Alternative names:
Zinc finger A20 domain-containing protein 2; Zinc finger protein 216
Alternative UPACC:
O76080; A8K484
Background:
AN1-type zinc finger protein 5, also known as Zinc finger A20 domain-containing protein 2 or Zinc finger protein 216, plays a crucial role in protein degradation through the ubiquitin-proteasome system. It anchors ubiquitinated proteins to the proteasome, regulating muscle atrophy, NF-kappa-B activation, and apoptosis. It inhibits NF-kappa-B activation induced by RIPK1, TRAF6, TNF, IL-1, and TLR4, and sensitizes cells to TNF-induced apoptosis. It also acts as an inhibitory factor for osteoclast differentiation.
Therapeutic significance:
Understanding the role of AN1-type zinc finger protein 5 could open doors to potential therapeutic strategies.